Suppr超能文献

肿瘤中表达的 A 类 G 蛋白偶联受体中同源结构位置的反复高频突变。

Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors.

机构信息

Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030.

Department of Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX 77030.

出版信息

Proc Natl Acad Sci U S A. 2021 Dec 21;118(51). doi: 10.1073/pnas.2113373118.

Abstract

G protein-coupled receptors (GPCRs) are the largest family of human proteins. They have a common structure and, signaling through a much smaller set of G proteins, arrestins, and effectors, activate downstream pathways that often modulate hallmark mechanisms of cancer. Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling similarly so as to favor a tumor. We hypothesized that somatic mutations in tumor samples may not be enriched within a single gene but rather that cognate mutations with similar effects on GPCR function are distributed across many receptors. To test this possibility, we systematically aggregated somatic cancer mutations across class A GPCRs and found a nonrandom distribution of positions with variant amino acid residues. Individual cancer types were enriched for highly impactful, recurrent mutations at selected cognate positions of known functional motifs. We also discovered that no single receptor drives this pattern, but rather multiple receptors contain amino acid substitutions at a few cognate positions. Phenotypic characterization suggests these mutations induce perturbation of G protein activation and/or β-arrestin recruitment. These data suggest that recurrent impactful oncogenic mutations perturb different GPCRs to subvert signaling and promote tumor growth or survival. The possibility that multiple different GPCRs could moonlight as drivers or enablers of a given cancer through mutations located at cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential approaches to therapeutics.

摘要

G 蛋白偶联受体(GPCRs)是人类蛋白中最大的家族。它们具有共同的结构,通过数量少得多的 G 蛋白、 arrestin 和效应器进行信号转导,激活下游通路,这些通路常常调节癌症的标志性机制。由于 GPCR 比效应器多得多,不同受体的突变可能以类似的方式扰乱信号,从而有利于肿瘤。我们假设肿瘤样本中的体细胞突变可能不会富集在单个基因中,而是具有相似 GPCR 功能影响的同源突变会分布在许多受体中。为了验证这一可能性,我们系统地汇总了 A 类 GPCR 中的体细胞癌症突变,发现具有变异氨基酸残基的位置存在非随机分布。个体癌症类型在已知功能基序的特定同源位置富集了具有高度影响的、复发性突变。我们还发现,没有单个受体驱动这种模式,而是多个受体在少数几个同源位置含有氨基酸取代。表型特征表明,这些突变诱导 G 蛋白激活和/或β-arrestin 募集的扰动。这些数据表明,复发性有影响的致癌突变通过位于 GPCR 同源物的同源位置的突变扰乱不同的 GPCR,从而颠覆信号转导并促进肿瘤生长或存活。多个不同的 GPCR 可以通过位于 GPCR 同源物的同源位置的突变作为给定癌症的驱动因子或促进因子发挥作用的可能性,为癌症机制和潜在治疗方法打开了一扇窗户。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d09a/8713800/1701f875a10b/pnas.2113373118fig01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验